Rating Change
Barclays analysts initiated coverage on Forte Biosciences, Inc. (NASDAQ:FBRX) with a Overweight rating on July 21, 2026.
new coverageNASDAQ:FBRX
Barclays Initiates Coverage on Forte Biosciences, Inc. (FBRX) with Overweight
Rating Change Barclays analysts initiated coverage on Forte Biosciences, Inc. (NASDAQ:FBRX) with a Overweight rating on July 21, 2026. Market Context Forte Biosciences, Inc.
Market Context
Forte Biosciences, Inc. operates in the Healthcare sector. The stock currently trades at $51.38 with a market capitalization of $284.1M.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Forte Biosciences, Inc..
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Forte Biosciences, Inc.
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Jul 21, 2026 | Barclays | Overweight | N/A |
| Nov 25, 2025 | Evercore ISI Group | Outperform | N/A |
| Nov 17, 2025 | Chardan Capital | Buy | N/A |
| Aug 18, 2025 | Guggenheim | Buy | N/A |
| Aug 15, 2025 | Chardan Capital | Buy | N/A |
Related Tools: Analyst Ratings Dashboard | View FBRX Stock Page
Frequently Asked Questions
What does a Overweight rating mean for FBRX?
A Overweight rating from Barclays reflects the analyst's outlook on Forte Biosciences, Inc. (NASDAQ:FBRX). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the FBRX forecast page.